 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Assistant Professor of Pharmacy, School of Pharmacy, Temple University, Philadelphia, PA
Associate Professor of Pharmacy, School of Pharmacy, Temple University
Reprints: Staci A Pacetti PharmD, School of Pharmacy, Temple University, 3307 N. Broad St., Philadelphia, PA 19140-5101, FAX 215/707-8326, E-mail spacetti{at}temple.edu
OBJECTIVE: To briefly discuss the changing epidemiology of fungal infections and review currently available agents; provide a review of caspofungin; and discuss its pharmacology, pharmacokinetics, dosing guidelines, safety and efficacy, and role in the treatment of invasive fungal infections as it relates to current antifungal therapy.
DATA SOURCES: A MEDLINE (1966 to August 2002) database search using key words caspofungin, echino candins, fungal infections, and invasive aspergillosis, was completed to identify relevant articles including reviews, recent studies, treatment guidelines, and data from Merck and Company.
STUDY SELECTION: In vitro studies and all clinical trials were evaluated to summarize the clinical efficacy and safety of caspofungin.
DATA SYNTHESIS: The incidence of fungal infections is increasing as the population at risk expands. Cost, resistance, and morbidity and mortality are key issues. Adding to the antifungal armamentarium is necessary to address these therapeutic dilemmas. Caspofungin is the first member of a new class of antifungal agents, the echinocandins, to be approved for clinical use. Caspofungin is classified as a glucan synthase inhibitor and represents a class of agents with a novel mechanism of action. Unlike currently available agents (polyenes, pyrimidines, azoles) that exert their effect on the fungal cell membrane, the echinocandins are the first agents to inhibit fungal cell wall synthesis. Caspofungin exhibits activity against Aspergillus spp. and Candida spp., including non-albicans species. Data from clinical trials demonstrate that caspofungin is effective in patients with invasive aspergillosis as well as candida esophagitis. Its Food and Drug Administration–approved indication is limited to invasive aspergillosis refractory to or intolerant of current therapy.
CONCLUSIONS: Caspofungin has activity against Aspergillus spp. as well as a variety of Candida spp. Clinical data support its usefulness in the treatment of invasive aspergillosis and select candida infections. As additional clinical data become available, it seems likely that the therapeutic role of caspofungin will expand.
Key Words: caspofungin acetate, fungal infections
www.theannals.com, DOI
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE
UNIVERSAL PROGRAM NUMBER: 407-000-03-001-H01
This article has been cited by other articles:
|
|
 |
|
  S. V. Balashov, S. Park, and D. S. Perlin Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1 Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2058 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Maligie and C. P. Selitrennikoff Cryptococcus neoformans Resistance to Echinocandins: (1,3){beta}-Glucan Synthase Activity Is Sensitive to Echinocandins Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2851 - 2856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Mukherjee, D. J. Sheehan, C. A. Hitchcock, and M. A. Ghannoum Combination Treatment of Invasive Fungal Infections Clin. Microbiol. Rev., January 1, 2005; 18(1): 163 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L Carver Micafungin Ann. Pharmacother., October 1, 2004; 38(10): 1707 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Kotloff, V. N. Ahya, and S. W. Crawford Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation Am. J. Respir. Crit. Care Med., July 1, 2004; 170(1): 22 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Odabasi, V. L. Paetznick, J. R. Rodriguez, E. Chen, and L. Ostrosky-Zeichner In Vitro Activity of Anidulafungin against Selected Clinically Important Mold Isolates Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1912 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Lodge, E. D. Ashley, M. P. Steele, and J. R. Perfect Aspergillus fumigatus Empyema, Arthritis, and Calcaneal Osteomyelitis in a Lung Transplant Patient Successfully Treated with Posaconazole J. Clin. Microbiol., March 1, 2004; 42(3): 1376 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grau and J. M.-d. Antonio Comment: caspofungin acetate for treatment of invasive fungal infections Ann. Pharmacother., December 1, 2003; 37(12): 1919 - 1919. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukuda, M. Boeckh, R. A. Carter, B. M. Sandmaier, M. B. Maris, D. G. Maloney, P. J. Martin, R. F. Storb, and K. A. Marr Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning Blood, August 1, 2003; 102(3): 827 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chan Comment: caspofungin acetate for treatment of invasive fungal infections Ann. Pharmacother., April 1, 2003; 37(4): 595 - 595. [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
